2026

The histone modifier KANSL2 is an actionable biomarker in multiple myeloma.
Jiang, Kaiting ORCID: https://orcid.org/0009-0000-3282-5953, Kirchner, Marieluise ORCID: https://orcid.org/0000-0002-7049-534X, Herzberg, Frederik ORCID: https://orcid.org/0009-0000-7338-7849, Zhao, Yan ORCID: https://orcid.org/0000-0002-3087-4767, Gasper, Amelie ORCID: https://orcid.org/0009-0003-5247-9498, Baumgartner, Francis ORCID: https://orcid.org/0000-0003-0768-1956, Jung, Paul ORCID: https://orcid.org/0000-0002-6447-450X, Braune, Jan ORCID: https://orcid.org/0000-0003-2026-2641, Schulze, Veronika ORCID: https://orcid.org/0009-0004-0823-1660, Isaakidis, Konstandina ORCID: https://orcid.org/0009-0002-7451-6889, Mertins, Philipp ORCID: https://orcid.org/0000-0002-2245-528X, Krönke, Jan ORCID: https://orcid.org/0000-0002-4649-0506, Wirth, Matthias ORCID: https://orcid.org/0000-0002-8340-0872, Keller, Ulrich ORCID: https://orcid.org/0000-0002-8485-1958 and Habringer, Stefan ORCID: https://orcid.org/0000-0002-3976-9592
Molecular Cancer Therapeutics 25 (6): 1016-1029. 1 June 2026

2024

Elimusertib has antitumor activity in preclinical patient-derived pediatric solid tumor models.
Pusch, F.F. ORCID: https://orcid.org/0000-0002-7152-080X, Dorado Garcia, H. ORCID: https://orcid.org/0000-0002-2578-3350, Xu, R. ORCID: https://orcid.org/0000-0002-5618-246X, Gürgen, D. ORCID: https://orcid.org/0000-0001-9241-6537, Bei, Y. ORCID: https://orcid.org/0000-0002-2104-8025, Brückner, L. ORCID: https://orcid.org/0000-0002-6155-2277, Röefzaad, C. ORCID: https://orcid.org/0000-0003-2299-6673, von Stebut, J. ORCID: https://orcid.org/0000-0001-9811-445X, Bardinet, V. ORCID: https://orcid.org/0000-0002-9583-7043, Chamorro Gonzalez, R. ORCID: https://orcid.org/0000-0002-5653-7259, Eggert, A. ORCID: https://orcid.org/0000-0003-3476-8184, Schulte, J.H. ORCID: https://orcid.org/0000-0003-0671-1201, Hundsdörfer, P. ORCID: https://orcid.org/0009-0007-1158-5170, Seifert, G. ORCID: https://orcid.org/0000-0002-7109-9277, Haase, K. ORCID: https://orcid.org/0000-0002-0944-5618, Schäfer, B.W. ORCID: https://orcid.org/0000-0001-5988-2915, Wachtel, M. ORCID: https://orcid.org/0000-0002-6077-3692, Kühl, A.A. ORCID: https://orcid.org/0000-0003-2293-5387, Ortiz, M.V. ORCID: https://orcid.org/0000-0001-9379-314X, Wengner, A.M. ORCID: https://orcid.org/0009-0009-5772-1945, Scheer, M. ORCID: https://orcid.org/0000-0002-0665-6268 and Henssen, A.G. ORCID: https://orcid.org/0000-0003-1534-778X
Molecular Cancer Therapeutics 23 (4): 507-519. 2 April 2024

2016

ERK1 as a therapeutic target for dendritic cell vaccination against high-grade gliomas.
Ku, M.C. ORCID: https://orcid.org/0000-0003-0963-2461, Edes, I., Bendix, I. ORCID: https://orcid.org/0000-0002-9751-3640, Pohlmann, A. ORCID: https://orcid.org/0000-0002-8572-2568, Waiczies, H., Prozorovski, T., Günther, M., Martin, C., Pagès, G., Wolf, S.A. ORCID: https://orcid.org/0000-0003-0922-8418, Kettenmann, H. ORCID: https://orcid.org/0000-0001-8208-0291, Uckert, W., Niendorf, T. ORCID: https://orcid.org/0000-0001-7584-6527 and Waiczies, S. ORCID: https://orcid.org/0000-0002-9916-9572
Molecular Cancer Therapeutics 15 (8): 1975-1987. August 2016

CD20-targeting immunotherapy promotes cellular senescence in B-cell lymphoma.
Däbritz, J.H.M., Yu, Y. ORCID: https://orcid.org/0000-0003-1928-2514, Milanovic, M. ORCID: https://orcid.org/0000-0003-1860-6003, Schönlein, M., Rosenfeldt, M.T., Dörr, J.R. ORCID: https://orcid.org/0000-0002-4927-6548, Kaufmann, A.M., Dörken, B. ORCID: https://orcid.org/0000-0001-7991-3643 and Schmitt, C.A. ORCID: https://orcid.org/0000-0002-4731-2226
Molecular Cancer Therapeutics 15 (5): 1074-1081. May 2016

Developing antagonists for the Met-HGF/SF protein-protein interaction using a fragment-based approach.
Winter, A., Sigurdardottir, A.G., DiCara, D., Valenti, G., Blundell, T.L. and Gherardi, E.
Molecular Cancer Therapeutics 15 (1): 3-14. January 2016

2010

Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy.
Brueckner, B., Rius, M., Rivera Markelova, M., Fichtner, I., Hals, P.A., Sandvold, M.L. and Lyko, F.
Molecular Cancer Therapeutics 9 (5): 1256-1264. May 2010

2007

Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression.
Walther, W. ORCID: https://orcid.org/0000-0003-2884-0231, Arlt, F., Fichtner, I., Aumann, J., Stein, U. ORCID: https://orcid.org/0000-0001-7006-282X and Schlag, P.M.
Molecular Cancer Therapeutics 6 (1): 236-243. January 2007

2006

Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway.
Hu, H., Jiang, C., Schuster, T., Li, G.X., Daniel, P.T. and Lue, J.
Molecular Cancer Therapeutics 5 : 1873-1882. July 2006

2005

Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM.
Becker, M., Sommer, A., Kraetzschmar, J.R., Seidel, H., Pohlenz, H.D. and Fichtner, I.
Molecular Cancer Therapeutics 4 : 151-170. 1 January 2005

2002

Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
Bradshaw, T.D., Bibby, M.C., Double, J.A., Fichtner, I., Cooper, P.A., Alley, M.C., Donohue, S., Stinson, S.F., Tomaszewjski, J.E., Sausville, E.A. and Stevens, M.F.G.
Molecular Cancer Therapeutics 1 (4): 239-246. 1 February 2002